Chembio Diagnostics (CEMI) Earns Media Impact Rating of 0.23

News articles about Chembio Diagnostics (NASDAQ:CEMI) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Chembio Diagnostics earned a news impact score of 0.23 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 47.186440878926 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the media headlines that may have impacted Accern Sentiment’s scoring:

Several research firms have recently commented on CEMI. ValuEngine upgraded shares of Chembio Diagnostics from a “buy” rating to a “strong-buy” rating in a report on Friday, June 1st. Benchmark began coverage on shares of Chembio Diagnostics in a report on Wednesday, July 11th. They issued a “buy” rating and a $14.00 price target for the company.

Shares of Chembio Diagnostics stock traded up $0.45 on Friday, reaching $11.45. The stock had a trading volume of 34,389 shares, compared to its average volume of 24,892. The company has a quick ratio of 3.86, a current ratio of 3.53 and a debt-to-equity ratio of 0.02. Chembio Diagnostics has a 1 year low of $5.75 and a 1 year high of $11.50. The company has a market cap of $155.91 million, a P/E ratio of -22.02 and a beta of 1.40.

Chembio Diagnostics (NASDAQ:CEMI) last issued its quarterly earnings data on Wednesday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.05). Chembio Diagnostics had a negative return on equity of 26.91% and a negative net margin of 16.54%. The firm had revenue of $8.72 million during the quarter, compared to analysts’ expectations of $6.94 million. equities research analysts forecast that Chembio Diagnostics will post -0.22 EPS for the current fiscal year.

Chembio Diagnostics Company Profile

Chembio Diagnostics, Inc, together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or monitor diseases. It offers tests for HIV and Syphilis, and Zika virus. The company also develops tests for malaria, Dengue virus, chikungunya virus, Ebola, Lassa, Marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi.

Further Reading: How Do I Invest in Dividend Stocks

Insider Buying and Selling by Quarter for Chembio Diagnostics (NASDAQ:CEMI)

Receive News & Ratings for Chembio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics and related companies with's FREE daily email newsletter.

Leave a Reply

Leave a Reply